WO2000076457A3 - Antagonistes du recepteur il-8 - Google Patents

Antagonistes du recepteur il-8 Download PDF

Info

Publication number
WO2000076457A3
WO2000076457A3 PCT/US2000/016500 US0016500W WO0076457A3 WO 2000076457 A3 WO2000076457 A3 WO 2000076457A3 US 0016500 W US0016500 W US 0016500W WO 0076457 A3 WO0076457 A3 WO 0076457A3
Authority
WO
WIPO (PCT)
Prior art keywords
chemokine
receptor antagonists
receptor
binds
treating
Prior art date
Application number
PCT/US2000/016500
Other languages
English (en)
Other versions
WO2000076457A2 (fr
Inventor
Gregory Martin Benson
Katherine L Widdowson
Original Assignee
Smithkline Beecham Corp
Gregory Martin Benson
Katherine L Widdowson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp, Gregory Martin Benson, Katherine L Widdowson filed Critical Smithkline Beecham Corp
Priority to JP2001502797A priority Critical patent/JP2003501450A/ja
Priority to AU60512/00A priority patent/AU6051200A/en
Priority to EP00946813A priority patent/EP1194143A4/fr
Publication of WO2000076457A2 publication Critical patent/WO2000076457A2/fr
Publication of WO2000076457A3 publication Critical patent/WO2000076457A3/fr
Priority to HK02106334.0A priority patent/HK1044717A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La présente invention concerne un procédé de traitement d'une maladie liée à la chimiokine dans lequel la chimiokine se lie à un récepteur IL-8 α ou β. Ce procédé consiste à administrer une quantité efficace d'un composé de formule (I) ou d'un de ses sels pharmaceutiquement acceptable. La chimiokine est plus spécifiquement l'interleukine 8 (IL-8).
PCT/US2000/016500 1999-06-15 2000-06-15 Antagonistes du recepteur il-8 WO2000076457A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2001502797A JP2003501450A (ja) 1999-06-15 2000-06-15 Ｉｌ−８受容体アンタゴニスト
AU60512/00A AU6051200A (en) 1999-06-15 2000-06-15 Il-8 receptor antagonists
EP00946813A EP1194143A4 (fr) 1999-06-15 2000-06-15 Antagonistes du recepteur il-8
HK02106334.0A HK1044717A1 (zh) 1999-06-15 2002-08-27 Il-8受體拮抗劑

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13968099P 1999-06-15 1999-06-15
US60/139,680 1999-06-15

Publications (2)

Publication Number Publication Date
WO2000076457A2 WO2000076457A2 (fr) 2000-12-21
WO2000076457A3 true WO2000076457A3 (fr) 2001-05-17

Family

ID=22487818

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/016500 WO2000076457A2 (fr) 1999-06-15 2000-06-15 Antagonistes du recepteur il-8

Country Status (6)

Country Link
EP (1) EP1194143A4 (fr)
JP (1) JP2003501450A (fr)
AU (1) AU6051200A (fr)
CO (1) CO5190710A1 (fr)
HK (1) HK1044717A1 (fr)
WO (1) WO2000076457A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8513302B2 (en) 2003-04-03 2013-08-20 The Regents Of The University Of California Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1608319A4 (fr) 2003-04-03 2007-02-28 Univ California Inhibiteurs ameliores pour hydrolase epoxyde soluble
US7662910B2 (en) 2004-10-20 2010-02-16 The Regents Of The University Of California Inhibitors for the soluble epoxide hydrolase
AR059826A1 (es) 2006-03-13 2008-04-30 Univ California Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble
EP2528604B1 (fr) 2010-01-29 2017-11-22 The Regents of the University of California Inhibiteurs d'acyl pipéridine d'époxyde hydrolase soluble

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4008326A (en) * 1973-12-26 1977-02-15 The Upjohn Company Substituted ureas and thioureas and pharmaceutical compositions thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11503110A (ja) * 1995-02-17 1999-03-23 スミスクライン・ビーチャム・コーポレイション Ｉｌ−８受容体拮抗剤
WO1997049399A1 (fr) * 1996-06-27 1997-12-31 Smithkline Beecham Corporation Antagonistes des recepteurs d'il-8

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4008326A (en) * 1973-12-26 1977-02-15 The Upjohn Company Substituted ureas and thioureas and pharmaceutical compositions thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8513302B2 (en) 2003-04-03 2013-08-20 The Regents Of The University Of California Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids

Also Published As

Publication number Publication date
AU6051200A (en) 2001-01-02
CO5190710A1 (es) 2002-08-29
WO2000076457A2 (fr) 2000-12-21
HK1044717A1 (zh) 2002-11-01
EP1194143A2 (fr) 2002-04-10
EP1194143A4 (fr) 2004-02-04
JP2003501450A (ja) 2003-01-14

Similar Documents

Publication Publication Date Title
WO1997020823A3 (fr) Antagonistes de recepteurs
WO2003037271A3 (fr) Composes, compositions pharmaceutiques et methodes d'utilisation
WO2002053177A3 (fr) Agents et methodes de traitement de la douleur
WO2002060392A3 (fr) Utilisation d'antagonistes du recepteur gal3 dans le traitement de la depression et/ou de l'anxiete et composes utiles dans de telles methodes
WO2001009138A3 (fr) Antagonistes du recepteur de chimiokine et procedes d'utilisation associes
MXPA03009644A (es) Grupos azabiciclicos sustituidos para el tratamiento de enfermedades.
BR0308904A (pt) Método de tratamento de gastroparesia, e, uso de um composto de glp-1
WO2003048164A3 (fr) Antagonistes du recepteur a2a de l'adenosine
WO2001001972A3 (fr) ANTAGONISTES SELECTIFS DU RECEPTEUR iGluR5 UTILISES DANS LE TRAITEMENT DE LA MIGRAINE
WO2000027850A3 (fr) Antagonistes de recepteurs du crf et methodes associees
AU2002241736A1 (en) Method for preventing or treating pain by administering an endothelin antagonist
TR200103680T2 (tr) IL-8 reseptör antagonistleri.
WO2002093173A3 (fr) Procede de criblage au moyen de pim1-kinase ou pim3-kinase
WO1997010824A8 (fr) Utilisation d'antagonistes du recepteur 5ht1b pour le traitement de maladies vasculaires
WO2001039723A3 (fr) Composes triazospiro presentant une affinite pour le recepteur de la nociceptine
CA2311423A1 (fr) Methode pour le traitement de l'hyperlipidemie
NZ514696A (en) IL-8 receptor antagonists
IL145645A0 (en) N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists
WO2000076457A3 (fr) Antagonistes du recepteur il-8
BR0007686A (pt) Uso de antagonistas receptores da angiotensina ii para tratar enfartação miocárdia aguda
WO2000053148A3 (fr) Procedes et compositions pour le traitement de la dyserection
WO2003045942A3 (fr) Antagonistes des recepteurs de la chimiokine et methodes d'utilisation de ces antagonistes
WO1998020835A3 (fr) Methode pour traiter l'hyperlipidemie chez l'homme
WO2000004012A8 (fr) COMPOSES SPECIFIQUES DU RECEPTEUR ADRENERGIQUE α1d HUMAIN ET SES UTILISATIONS
WO2001009119A3 (fr) Antagonistes de recepteur de chimiokine et procedes d'utilisation associes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AU BA BB BG BR CA CN CZ DZ EE GE GH GM HR HU ID IL IN IS JP KP KR LC LK LR LT LV MA MG MK MN MX MZ NO NZ PL RO SG SI SK SL TR TT TZ UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AU BA BB BG BR CA CN CZ DZ EE GE GH GM HR HU ID IL IN IS JP KP KR LC LK LR LT LV MA MG MK MN MX MZ NO NZ PL RO SG SI SK SL TR TT TZ UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000946813

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09980306

Country of ref document: US

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 502797

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 2000946813

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000946813

Country of ref document: EP